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Editorials 
A new look at the natural history of aspergillus 
hypersensitivity in asthmatics 
Introduction 
Aspergillus fumigatus had long been recognized 
as a pulmonary pathogen, forming mycetomas in 
pre-formed cavities and/or invading lung tissue in 
immunocompromised patients. The discovery of 
its capacity to induce IgE-mediated hypersensitivity 
and cause bronchial and lung damage through 
immunologically-mediated mechanisms is more 
recent. Allergic bronchopulmonary aspergillosis 
(ABPA) was first described in 1952 (1) and for a time 
was considered to be a British disease. In due course 
however it was recognized in other countries (2-4), 
and its discovery led to reappraisal of the significance 
of aspergillus hypersensitivity (AH), usually defined 
for clinical purposes as the presence of an immediate- 
type cutaneous reaction to commercial extracts of 
A. fimigatus or to an aspergillus mix. In particular, 
attention has focused on the prevalence of AH, 
pulmonary and environmental factors that predis- 
pose to its development, the relationship between AH 
and tissue-damaging events like ABPA and its 
longterm course and natural history. As it is more 
than 40 years since this phenomenon first attracted 
interest, it is relevant to review how knowledge and 
recommendations have changed. 
Prevalence of Aspergillus Hypersensitivity in Adult 
Asthmatics 
The incidence of positive skin reactions to A. 
fumigatus in unselected extrinsic asthmatics in the 
U.K. ranges from 10 to 25% (5). Similar figures have 
been reported from the U.S.A. (6), but regional 
differences might exist. In Cape Town, South Africa, 
which has a Mediterranean climate very similar to 
California, 44% of adult patients referred to a spe- 
cialist respiratory clinic for assessment of suspected 
asthma react to A. jiimigatus or an aspergillus mix 
(7). This proportion of reactive patients has remained 
constant over the past two decades, and aspergillus 
ranks fourth as a cause of positive reactions after the 
house dust mite, feathers and grass pollen (7). When 
performed by the intradermal rather than the skin 
prick method, a large proportion of patients also 
demonstrate a late-phase cutaneous response. A 
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positive IgE-A. fumigatus RAST titre is found in 
approximately 50% of patients with positive skin 
reactions, particularly those with a late-phase 
response (8). 
Factors Favouring the Development of Aspergillus 
Hypersensitivity 
The aspergillus fungus is found world-wide in soil 
and decaying vegetable matter, with peak atmo- 
spheric concentrations of spores occurring during 
winter. Average atmospheric A. fumigatus spore 
concentrations in Cambridge (9) and Cardiff (lo), 
St Louis (10) and Cape Town (7) are similar, but it 
is likely that in fungal-induced disease the micro- 
environment in the home and at work is more 
important than it is in pollen allergy. High counts 
have been reported in hospital wards in the U.K. 
(11) and in homes (4,12), and in individual cases 
ABPA has been linked to living near a municipal 
leaf compost site (13) and to occupational 
exposures (14). 
High concentrations alone do not account for the 
high incidence of sensitization to this fungus, as in 
both outdoor and indoor air other fungi are found in 
greater numbers. Instead this tendency results from 
the size of their spores (2.5-3pm) which favours 
inhalation and peripheral deposition in the lung, and 
their thermotolerance which enables them to grow at 
body temperature. Thus their numbers in sputum 
and in specimens from bronchi sampled at post- 
mortem are high relative to other atmospheric fungi 
(15). 
A prerequisite for the development AH is sustained 
or repeated exposure to aspergillus antigen. Two 
distinct antigens Asp f I (a 18 kDa protein) and a 
45 kDa protein have been identified as important 
causes of IgE antibody responses in patients with an 
immediate response to A. fumigatus (8). Exposure 
results from colonization of the respiratory tract 
within cavities of healed tuberculosis or sarcoid- 
osis, abnormal bronchi found in cystic fibrosis (16) 
and other forms of bronchiectasis (17) and rarely 
in the middle ear and paranasal sinuses. Recently 
sensitization has been described after colonization of 
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residual cavities caused by pneumocystis pneumonia 
in patients with AIDS (18). Growth of fungi in any of 
these locations permits sustained presentation of 
antigen to the host immunological system and the 
opportunity for stimulating IgE production and/or 
inducing predominantly IgG-related immunopathol- 
ogy. In atopic subjects features of AH precede the 
development of more complex tissue-damaging 
pathology whereas in non-atopic patients a larger 
antigenic load as in the case of an aspergilloma may 
provoke high concentrations of IgG antibodies with- 
out the development of hypersensitivity. As AH is 
rare in non-asthmatic atopic subjects, it is suggested 
that asthmatic airways provide favourable conditions 
for colonization with aspergillus, possibly through 
increased trapping of air-borne spores or impaired 
clearance. The incidence of A. jiimigatus is highest in 
long-standing asthmatics with asthma dating to 
childhood, those sensitive to several additional aero- 
antigens, and in patients with severe asthma requir- 
ing multi-drug therapy (7). The role of local factors 
rather than genetically determined atopic predisposi- 
tion is suggested in cystic fibrosis, where up to 12% 
develop features of ABPA (16). 
What is the Significance of a Positive Skin Reaction 
to Aspergillus Antigen? 
A distinction must be made between a positive 
reaction to A. fumigatus obtained in the commonly 
used skin prick test, and that occurring after intra- 
dermal testing. The wheal size is larger and incidence 
of late-phase reactions higher after intradermal test- 
ing. This method is advised for patients in whom 
ABPA is suspected, and initial skin prick testing is 
negative (19). Skin prick reactions to A. fumigatus are 
usually smaller than those to house dust mite and 
induration of as little as 3 mm greater than that 
obtained with the diluent indicates hypersensitivity. 
As cross-reactivity exists between commercially avail- 
able preparations of different aspergillus species, 
individual differences should be interpreted with cau- 
tion. Although 95% of cases of ABPA are caused by 
A. jiimigatus, rare cases caused by Aspergillus niger, 
terreus (20) and oryzae (14) have been described. It is 
therefore recommended that A. fimigatus and an 
aspergillus mix be included in the allergy work-up of 
all asthmatics. Positive reactions may be expected in 
a quarter of subjects tested and ABPA diagnosed in 
approximately 5% of these (less than 2% of all 
asthmatics). 
The relevance of AH to asthma symptoms is 
unclear. In ABPA, worsening of symptoms is fre- 
quently associated with immunological evidence of 
increased reactivity to aspergillus (8,19). No such 
relationship has been demonstrated in asthmatics 
with AH alone. Most have evidence of other sensi- 
tivities, usually to house dust mite and pollen. Thus, 
its relevance cannot be assumed except where it 
occurs as an isolated or dominant reaction. Bronchial 
allergen challenge is not recommended as it is 
costly, potentially hazardous, provides no additional 
clinically useful information, and treatment is not 
materially altered by a positive finding. 
What is the Relationship Between Aspergillus 
Hypersensitivity and ABPA? 
An exaggerated form of AH is a component of 
ABPA and is responsible for several of the features of 
this condition. Clinically, ABPA manifests as bron- 
chial asthma with transient pulmonary infiltrates that 
may proceed to proximal bronchiectasis and lung 
fibrosis. Laboratory findings include sputum and 
blood eosinophilia, markedly elevated serum IgE 
level, positive IgE-A. fumigatus, and IgG-A. fumiga- 
tus and precipitating antibodies to A. fumigatus- 
allergens (19,20). Because of its relationship to 
ABPA, AH has been viewed as the first phase in the 
development of ABPA. Although this may be so, the 
progression is seen in a small minority of patients. In 
a longitudinal survey of patients in our clinic fol- 
lowed for a minimum of 10 years on conventional 
asthma treatment, skin reactivity to A. furnigatus and 
other features of sensitization including RAST, and 
in some, precipitating antibodies resolved in a signifi- 
cant proportion of subjects and none went on to 
develop ABPA. Identification of patients who might 
progress to ABPA is complicated by the fact that the 
features of ABPA vary according to the stage of 
disease and the effect of modifying treatment with 
systemic corticosteroids (19). Serological tests have 
been used to identify the stage of development in 
individual asthmatics. Specific serum immunological 
patterns have been recognized, which distinguish 
asthma with AH from the remission, intermediate 
and active phases of ABPA (21). In the former 
IgE-A. fumigatus RAST titres are low but they are 
invariably high in active ABPA. Titres of A. 
fumigatus-specific IgE measured by ELIZA show 
similar differences. Utilizing an immuno-blotting 
technique to detect serum IgE and IgG fractions 
directed at a variety of A. fumigatus antigens, patients 
with active ABPA exhibit reactions with up to 12 
major A. fumigatus allergens, while patients in remis- 
sion react weakly to fewer than five major A. fumi- 
gations allergens, but have strong IgG-mediated 
reactions to high molecular weight A. fumigatus 
antigens (21). Fewer than 20% of patients with 
asthma and AH showed reactions on immunoblots 
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and these are generally weak. Although this tech- 
nique is not in general clinical use, the results illus- 
trate the continuum of immunological reactivity from 
AH to ABPA and its greater complexity and intensity 
during the active phase of ABPA. 
What is the Natural History of Aspergillus 
Hypersensitivity and the Influence of Treatment? 
In view of its tendency to resolve specific measures 
intended to reduce AH are unnecessary. However, 
early diagnosis of ABPA is important as treatment 
has been shown to control exacerbations, prevent 
relapses and the development of bronchiectasis and 
pulmonary fibrosis. Although systemic corticoster- 
oids are necessary for active ABPA and exacerba- 
tions, usual maintenance treatment of asthma of 
which inhaled corticosteroids form a central part are 
usually adequate and progression is rare. With time 
even patients with cystic fibrosis and ABPA may 
show improvement in respiratory status and reduced 
sensitization to A. firrtigatus (16). 
Prevention of AH is difficult to achieve since 
environmental measures are seldom effective except 
where a particular source is identified. Combined 
surgical and medical treatment of middle-ear and 
paranasal sinuses to eradicate aspergillus coloniza- 
tion in these locations is effective in rare instances. 
Treatment with itraconazole (22) and other azoles 
(23) has been proposed for patients with structural 
lung disease as a means of eradicating colonization 
and reducing the tendency to relapse. These initial 
studies suggest that they are of limited value, but 
further trials are necessary. 
E. D. BATEMAN 
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University of Cape Town and 
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